Skip to content

Myriad Genetics MYGN Legal settlements

Legal settlements at other companies

Ducommun logo
DucommunDCO
$7.63M
Commercial Metals logo
Commercial MetalsCMC
$90.57M
Aeva Technologies logo
Aeva TechnologiesAEVA
$0
McKesson logo
McKessonMCK
$1M
Viatris logo
ViatrisVTRS
-$53.5M-173%
Minerals Technologies logo
Minerals TechnologiesMTX
$8.8M+214%

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$512.85M+13.1%
Enterprise value$598.35M+17.3%
P/S0.6×+0.1×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept mygn:LegalFeesIncludingReversal.

The official record: Myriad Genetics’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's legal settlements.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Myriad Genetics's legal settlements?
Myriad Genetics (MYGN) reported legal settlements of $0 in Q4 2025.
How has Myriad Genetics's legal settlements changed year-over-year?
Myriad Genetics's legal settlements increased by 100.0% year-over-year, from -$5.33M to $0.
What does legal settlements mean?
This metric represents the net financial impact of legal settlements, litigation-related expenses, and any associated reversals or recoveries. It captures the costs or gains resulting from legal disputes, regulatory investigations, or patent litigation that fall outside of normal operating activities. Investors monitor this to assess the company's exposure to legal risks and the potential volatility these non-recurring events introduce to the bottom line.